Dr. Reddy’s Expands GLP-1 Portfolio with Launch of Oral Semaglutide Biosimilar in India
Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1...
Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1...
Key Highlights: Implications: Usema adds another early...